Form 4 Filing for 4D Molecular Therapeutics, Inc.

This filing details a Form 4 submission for 4D Molecular Therapeutics, Inc. regarding stock options granted to Nancy Miller-Rich, a director. The transaction date was June 17, 2026. The filing includes a stock option grant for 50,000 shares of Common Stock, with an exercise price of $9.42 per share. The option vests in three tranches, with 1/3 vesting on June 17, 2027, and the remainder vesting monthly until June 17, 2029. Full vesting is contingent upon continued service and may occur earlier upon a Change in Control. The option expires on June 16, 2036. This grant was automatically awarded per the company's non-employee director compensation program.